Posted on 22/07/2010 in Medical Company Financials Boston Scientific has expressed satisfaction with its financial performance in the second quarter of 2010 after exceeding internal expectations in a number of areas.
Net sales for the three-month period came to $1.9 billion (1.2 billion pounds), which represented a slight decline compared to the $2.1 billion figure recorded in Q2 2009.
However, the firm was nevertheless positive about its overall performance, with new products such as the Promus Element stent delivering around 44 per cent of total sales.
It also highlighted the better-than-expected results from its cardiac rhythm management division, which it attributed to the "exceptional execution" of sales initiatives by its staff.
Other achievements during the quarter included the launch of the Taxus Element paclitaxel-eluting coronary stent and the launch of several clinical trials.
Ray Elliott, president and chief executive officer of Boston Scientific, said: "I am proud of the way the organisation executed in a number of key areas during the quarter."
Earlier this month, Boston Scientific commenced enrolment for MultiSENSE, a clinical study which is hoped will allow for the development of improved heart failure monitoring technology.Other news stories from 22/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
